Structure-based drug design

Protein crystallography for macromolecular structure determination

Structure-based drug design (SBDD, also known as rational drug design) is a technique that accelerates the drug discovery process by utilizing structural information to improve the lead optimization process. It has been estimated that SBDD can reduce the cost from target identification to investigational new drug (IND) filing by 50%. The technique requires a high-resolution 3D structure of the inhibitor bound to the target obtained using X-ray crystallography. Once the structure is obtained, the interactions between the inhibitor and the active site of the target are analyzed. Improved inhibitors result from this analysis, resulting in a shortening of the lead optimization process.


X-ray Diffraction systems
  XtaLAB Synergy-R
Single crystal diffraction system with MicroMax-007 HF microfocus rotating anode generator
    XtaLAB Synergy-S
Fast, flexible system with the latest generation sources and HPC detectors, perfect for any crystallography lab.
  XtaLAB Synergy Custom
Single crystal diffraction system with custom enclosure and flexibility for easy integration of accessory components